FAScinate Therapeutics Completes Part 1a of Phase 2 Study of Company's Parkinson’s Disease Drug Candidate "KM-819" Read Now >
Thursday, January 12, 2023 / PRWeb
Thursday, January 12, 2023 / PRWeb
Tuesday, November 23, 2021 / BioSpace
Wednesday, November 17, 2021 / PRWeb
Wednesday, November 17, 2021 / Parkinson's News Today
Friday, November 5, 2021 / FAScinate Therapeutics
Monday, January 7, 2019 / Senior Health News